{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T19:13:14Z","timestamp":1768072394729,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s13555-022-00704-2","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T08:02:41Z","timestamp":1647158561000},"page":"911-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct01474512","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01597245","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01646177","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03573323","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02561806","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03151551","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Boni E.","family":"Elewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Missy","family":"McKean-Matthews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russel","family":"Burge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyn C.","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,13]]},"reference":[{"issue":"6","key":"704_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","volume":"58","author":"AB Kimball","year":"2008","unstructured":"Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"704_CR2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2340\/00015555-1273","volume":"92","author":"F Sampogna","year":"2012","unstructured":"Sampogna F, Tabolli S, Abeni D. Investigators IMPRoVEI. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299\u2013303.","journal-title":"Acta Derm Venereol"},{"key":"704_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"9993","key":"704_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"21","key":"704_CR5","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1612334","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102.","journal-title":"N Engl J Med"},{"issue":"1","key":"704_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2018.06.039","volume":"80","author":"C Paul","year":"2019","unstructured":"Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70-9.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"704_CR7","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","volume":"184","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047\u201358.","journal-title":"Br J Dermatol"},{"issue":"1","key":"704_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123\u201331.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"704_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","volume":"10","author":"C Leonardi","year":"2020","unstructured":"Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb). 2020;10(3):431\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"704_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"704_CR11","first-page":"1086","volume":"14","author":"IF Manalo","year":"2015","unstructured":"Manalo IF, Gilbert KE, Wu JJ. Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol. 2015;14(10):1086\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"704_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1365-2133.2010.09831.x","volume":"163","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Blome C, Sch\u00e4fer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580\u20135.","journal-title":"Br J Dermatol"},{"issue":"4","key":"704_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","volume":"94","author":"F Sampogna","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"704_CR14","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.","journal-title":"Dermatol Ther"},{"issue":"1","key":"704_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"704_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000316169","volume":"221","author":"R Baran","year":"2010","unstructured":"Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(Suppl 1):1\u20135.","journal-title":"Dermatology"},{"issue":"5","key":"704_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/bjd.13272","volume":"171","author":"A Langenbruch","year":"2014","unstructured":"Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123\u20138.","journal-title":"Br J Dermatol"},{"issue":"7","key":"704_CR18","first-page":"1315","volume":"33","author":"R Scarpa","year":"2006","unstructured":"Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"704_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"704_CR20","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jdv.12368","volume":"28","author":"KM Klaassen","year":"2014","unstructured":"Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28(12):1690\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"704_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00704-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00704-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T10:06:11Z","timestamp":1650535571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00704-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00704-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}